» Articles » PMID: 12175394

The Quality of Life in Men After Radical Cystectomy with a Continent Cutaneous Diversion or Orthotopic Bladder Substitution: is There a Difference?

Overview
Journal BJU Int
Specialty Urology
Date 2002 Aug 15
PMID 12175394
Citations 33
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To compare the quality of life (QoL) in men after radical cystectomy who had either a continent cutaneous diversion or orthotopic bladder substitution.

Patients And Methods: Eighty men with at least 6 months of follow-up and with no signs of recurrent disease after radical cystectomy for bladder carcinoma, and who had either a continent cutaneous diversion or orthotopic bladder substitution, were sent two types of questionnaire, the Functional Assessment of Cancer Therapy-Bladder Cancer (FACT-Bl) and the Hospital Anxiety and Depression Scale (HADS), to determine their QoL.

Results: The FACT-Bl and HADS questionnaires were returned by 90% and 71% of the patients, respectively (P < 0.05). In the replies to the generic version of FACT-Bl there were no differences between the groups in any domain, the scores being high in all. In questions covering intestinal, urinary and sexual items, patients with continent diversion had less trouble controlling urine (P < 0.0001), had to empty less often (P < 0.001), and had fewer symptoms when emptying (P < 0.05). Patients with neobladders had a better appreciation of appearance and better preserved erectile function (both P < 0.05). In the answers to the HADS, the mean scores were low (within the normal ranges) and did not differ between the groups.

Conclusion: Using two instruments tested for validity and reliability, there were no differences between patients with continent diversion and those with orthotopic substitution.

Citing Articles

Health-related quality of life after radical cystectomy for bladder cancer in elderly patients with ileal orthotopic neobladder, ureterocutaneostomy or ileal conduit: cross-sectional study using validated questionnaires.

Altunkol A, Alma E, Vuruskan E, Cetinkoku G, Karkin K, Aydamirov M BMC Urol. 2025; 25(1):46.

PMID: 40065307 PMC: 11892295. DOI: 10.1186/s12894-025-01730-w.


Cepharanthine inhibits migration, invasion, and EMT of bladder cancer cells by activating the Rap1 signaling pathway in vitro.

Chen B, Chen L, Yang J, Hou M, Cai Q, Dai W Am J Transl Res. 2024; 16(5):1602-1619.

PMID: 38883391 PMC: 11170605. DOI: 10.62347/WDFF7432.


Factors Influencing Quality of Life and Functional Outcomes in Patients With Bladder Cancer.

Zhou Q, Chen X, Chen Q, Hao L Cancer Control. 2023; 30:10732748231212353.

PMID: 37907433 PMC: 10621294. DOI: 10.1177/10732748231212353.


Female sexual function evaluation and intraoperative vaginal reconstruction in bladder cancer.

Orji P, Sun H, Isali I, Bell S, Zaorsky N, Mishra K World J Urol. 2023; 41(7):1751-1762.

PMID: 37419972 DOI: 10.1007/s00345-023-04502-z.


Neobladder "Function": Tips and Tricks for Surgery and Postoperative Management.

Fasanella D, Marchioni M, Domanico L, Franzini C, Inferrera A, Schips L Life (Basel). 2022; 12(8).

PMID: 36013372 PMC: 9409805. DOI: 10.3390/life12081193.